Zobrazeno 1 - 10
of 254
pro vyhledávání: '"Filip, van den Bosch"'
Autor:
Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van derHeijde, Tae‐Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Yihan Li, Kristin D'Silva, Peter Wung, In‐Ho Song
Publikováno v:
ACR Open Rheumatology, Vol 6, Iss 8, Pp 470-480 (2024)
Objective Upadacitinib improved the signs and symptoms of non‐radiographic axial spondyloarthritis (nr‐axSpA) versus placebo over 14 weeks in the primary analysis of the SELECT‐AXIS 2 nr‐axSpA study. Here, we evaluated the efficacy and safety
Externí odkaz:
https://doaj.org/article/db103b5345e54f818689f724ae2c5979
Autor:
Filip van den Bosch, Martin Rudwaleit, Helena Marzo-Ortega, Natasha de Peyrecave, Victoria Navarro-Compán, Lars Bauer, Rachel Tham, Thomas Kumke, Mindy Kim
Publikováno v:
RMD Open, Vol 10, Iss 3 (2024)
Introduction This post hoc analysis evaluated the relationship between objective measures of inflammation and clinical outcomes following 12 weeks of certolizumab pegol (CZP) treatment in patients with active axial spondyloarthritis (axSpA).Methods W
Externí odkaz:
https://doaj.org/article/fdb0162a072d4d89a88c1d9b1c6ae796
Autor:
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, Byron Padilla, Alan Kivitz
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 633-648 (2024)
Abstract Introduction Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had
Externí odkaz:
https://doaj.org/article/9ce4042ecece4341be994d1a7b7901c4
Autor:
Roy Fleischmann, Ricardo Blanco, Filip Van den Bosch, Louis Bessette, Yanna Song, Sara K. Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 599-615 (2024)
Abstract Introduction This study aimed to describe the long-term efficacy and safety of upadacitinib and adalimumab through 228 weeks following immediate switch to the alternate therapy with a different mechanism of action (MoA) in patients with rheu
Externí odkaz:
https://doaj.org/article/bda276920acf4632bf961e69f50d248a
Autor:
Juergen Braun, Ricardo Blanco, Helena Marzo-Ortega, Lianne S. Gensler, Filip Van den Bosch, Stephen Hall, Hideto Kameda, Denis Poddubnyy, Marleen van de Sande, Désirée van der Heijde, Tingting Zhuang, Anna Stefanska, Aimee Readie, Hanno B. Richards, Atul Deodhar
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-12 (2023)
Abstract Background Radiographic progression and course of inflammation over 2 years in patients with non-radiographic axial spondyloarthritis (nr-axSpA) from the phase 3, randomized, PREVENT study are reported here. Methods In the PREVENT study, adu
Externí odkaz:
https://doaj.org/article/ded6f481e2124265b7316b8ec19b458f
Autor:
Filip van den Bosch, Kurt de Vlam, Rik Lories, Dirk Elewaut, Manouk de Hooge, Ann-Sophie De Craemer, Serge Steinfeld, Alla Ishchenko, Adrien Nzeusseu
Publikováno v:
RMD Open, Vol 9, Iss 2 (2023)
Background To examine radiographic axial damage of the sacroiliac joints and spine in patients with psoriatic arthritis (PsA) and spondyloarthritis (SpA) in private and academic Belgian practices.Methods Patients with PsA with clinical diagnosis of P
Externí odkaz:
https://doaj.org/article/6a00bca154874e02961bd7d500774574
Autor:
Jürgen Braun, Ricardo Blanco, Helena Marzo-Ortega, Lianne S. Gensler, Filip van den Bosch, Stephen Hall, Hideto Kameda, Denis Poddubnyy, Marleen van de Sande, Anna S. Wiksten, Brian O. Porter, Abhijit Shete, Hanno B. Richards, Sibylle Haemmerle, Atul Deodhar
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-10 (2021)
Abstract Background To investigate the efficacy of secukinumab in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) grouped by disease activity as assessed by C-reactive protein (CRP) levels and/or magnetic resonance imaging (M
Externí odkaz:
https://doaj.org/article/ff186d2670aa4999bb5a719f99db19ad
Autor:
Désirée van der Heijde, Filip van den Bosch, Atul Deodhar, Joachim Sieper, Bernard Combe, Walter P Maksymowych, In-Ho Song, Tae-Hwan Kim, Mitsumasa Kishimoto, Yuanyuan Duan, Yunxia Sui, Andrew J Östör, Peter K Wung
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported.Methods In SELECT-AXIS 1, patients receiving placebo were switched to upadacitinib 15 mg once daily at wee
Externí odkaz:
https://doaj.org/article/70da74d6d0eb473ab12c42387a181ffd
Autor:
Filip van den Bosch, Vibeke Strand, Cunshan Wang, Joseph C Cappelleri, Joseph Wu, Marina Magrey, James Cheng-Chung Wei, Victoria Navarro-Compán, Lisy Wang, Lara Fallon, Dona Fleishaker, Oluwaseyi Dina
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/bb08d9b2f36945409ceb39e02e7a8c8a
Autor:
Robert Landewé, Désirée van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Karl Gaffney, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Karen Thomas, Lianne S. Gensler
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 3, Pp 581-599 (2020)
Abstract Introduction Achievement of remission is a key treatment goal for patients with axial spondyloarthritis (axSpA). C-OPTIMISE assessed achievement of sustained clinical remission in patients with axSpA, including radiographic (r) and non-radio
Externí odkaz:
https://doaj.org/article/d24ddd10a84d4d3dac2c84f1bf9d36df